Catalent, Inc. (NYSE:CTLT – Get Free Report) insider John J. Greisch purchased 21,000 shares of the business’s stock in a transaction dated Wednesday, August 30th. The shares were purchased at an average price of $50.24 per share, for a total transaction of $1,055,040.00. Following the purchase, the insider now owns 34,000 shares of the company’s stock, valued at approximately $1,708,160. The purchase was disclosed in a filing with the SEC, which is accessible through this link.
Catalent Trading Up 0.5 %
Catalent stock opened at $50.20 on Friday. The company has a quick ratio of 1.34, a current ratio of 1.84 and a debt-to-equity ratio of 0.91. Catalent, Inc. has a 52 week low of $31.45 and a 52 week high of $97.54. The company has a market capitalization of $9.05 billion, a price-to-earnings ratio of -38.62, a price-to-earnings-growth ratio of 5.96 and a beta of 1.22. The stock has a 50-day moving average price of $45.89 and a 200 day moving average price of $50.38.
Catalent (NYSE:CTLT – Get Free Report) last released its earnings results on Tuesday, August 29th. The company reported $0.09 EPS for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.02). Catalent had a return on equity of 7.13% and a net margin of 0.93%. The firm had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.05 billion. During the same period last year, the firm earned $1.12 EPS. The company’s revenue for the quarter was down 15.6% compared to the same quarter last year. Sell-side analysts anticipate that Catalent, Inc. will post 0.83 EPS for the current year.
Wall Street Analyst Weigh In
Institutional Investors Weigh In On Catalent
Several hedge funds have recently bought and sold shares of CTLT. Cetera Advisor Networks LLC boosted its position in Catalent by 7.1% in the 1st quarter. Cetera Advisor Networks LLC now owns 1,953 shares of the company’s stock worth $217,000 after purchasing an additional 130 shares in the last quarter. Private Advisor Group LLC boosted its position in Catalent by 18.0% in the 1st quarter. Private Advisor Group LLC now owns 2,957 shares of the company’s stock worth $328,000 after purchasing an additional 452 shares in the last quarter. Panagora Asset Management Inc. boosted its position in Catalent by 125.8% in the 1st quarter. Panagora Asset Management Inc. now owns 12,979 shares of the company’s stock worth $1,439,000 after purchasing an additional 7,231 shares in the last quarter. Yousif Capital Management LLC boosted its position in Catalent by 2.0% in the 1st quarter. Yousif Capital Management LLC now owns 24,561 shares of the company’s stock worth $2,724,000 after purchasing an additional 470 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in shares of Catalent by 1.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 991,019 shares of the company’s stock worth $109,904,000 after buying an additional 17,813 shares during the period.
Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
- Five stocks we like better than Catalent
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- MarketBeat Week in Review – 8/28 – 9/1
- Why Invest in 5G? How to Invest in 5G Stocks
- 2 Stocks That Doubled EPS Estimates and Flashing Buy Signals
- Best Restaurant Stocks to Invest in Now
- Toyota vs Tesla: The Tortoise And The Hare Race Has A New Meaning
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.